文献速递糖尿病肥胖与代谢综合征

芬兰男性中矮身材预测β细胞功能受损、胰岛素抵抗、血糖升高及2型糖尿病

Short Adult Stature Predicts Impaired β-Cell Function, Insulin Resistance, Glycemia, and Type 2 Diabetes in Finnish Men.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

基于芬兰代谢综合征男性(METSIM)队列的8746名非糖尿病男性,平均年龄57.2±7.1岁、BMI 26.8±3.8 kg/m²,随访中5401人参与,693人转为2型糖尿病、351人发生新发心血管事件。结论认为矮身材与糖代谢不利变化相关,并预测2型糖尿病和心血管事件风险增加。

要点

  • 在芬兰非糖尿病男性中,基线身高较高与口服葡萄糖耐量试验2小时血糖较低相关。

核心结论

  • 矮身材与糖代谢的不利变化相关,并预测2型糖尿病和心血管事件风险增加。

研究设计与样本

  • 研究纳入来自基于人群的代谢综合征男性(METSIM)研究的8746名芬兰男性,平均年龄57.2±7.1岁,平均BMI 26.8±3.8 kg/m²,研究在库奥皮奥大学医院和东芬兰大学进行。
  • 参与者在招募时均非糖尿病,其中5401人参与了随访研究;随访期间共693人转为2型糖尿病,351人被诊断为新发心血管疾病事件。

主要发现

  • 基线身高与口服葡萄糖耐量试验2小时血糖较低显著相关。
  • 基线身高与胰岛素分泌增加显著相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Recent studies have highlighted the role of height in complex diseases, but conflicting information has been reported on height as a predictor of changes in glycemia and risk of type 2 diabetes. OBJECTIVE: Our aim was to investigate the association of height with insulin sensitivity, insulin secretion, glycemia, type 2 diabetes, and cardiovascular disease (CVD) in a large prospective population-based study. DESIGN: The study included 8746 Finnish men (mean ± standard deviation, age 57.2 ± 7.1 years, body mass index, 26.8 ± 3.8 kg/m2) selected from a population-based Metabolic Syndrome in Men (METSIM) study. SETTING: The study was conducted at Kuopio University Hospital and University of Eastern Finland. PARTICIPANTS: The participants were nondiabetic at the recruitment, and 5401 subjects have participated in the follow-up study. During the follow-up, a total of 693 subjects converted to type 2 diabetes and 351 were diagnosed with a new CVD event during the follow-up. MAIN OUTCOME MEASURES: The main outcome measures were incidence of type 2 diabetes and CVD. RESULTS: Height measured at baseline was significantly associated with lower levels of 2-hour glucose in an oral glucose tolerance test, an increase in insulin secretion, a decrease in the risk of type 2 diabetes [hazard ratio (HR) = 0.83(confidence interval [CI] 0.77 to 0.90)] and CVD [HR = 0.75(CI 0.67 to 0.83)] during the follow-up. CONCLUSION: Short stature is associated with unfavorable changes in glucose metabolism and predicts an increase in the risk of type 2 diabetes and cardiovascular events.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Vangipurapu J, Stancáková A, Jauhiainen R, et al. Short Adult Stature Predicts Impaired β-Cell Function, Insulin Resistance, Glycemia, and Type 2 Diabetes in Finnish Men. J Clin Endocrinol Metab. 2017. PMID: 27906553. doi:10.1210/jc.2016-2933

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。